Hey everyone —
The SELECT trial (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity), published in the New England Journal of Medicine on November 11, 2023, randomized 17,604 overweight or obese patients with established cardiovascular disease — and no diabetes — to weekly 2.4mg semaglutide or placebo. The result was a 20% reduction in major adverse cardiovascular events, the first proof that a weight-loss drug improves cardiovascular outcomes in a non-diabetic population.
Compounds covered in this article
THE TRIAL AT A GLANCE
Inclusion criteria were specific: age ≥45, BMI ≥27, pre-existing cardiovascular disease (prior MI, stroke, or peripheral artery disease), and no diabetes at baseline. That last criterion separated SELECT from all prior GLP-1 cardiovascular trials, which had enrolled diabetic populations. Separating cardiovascular benefit from glycemic effect required a non-diabetic cohort — SELECT was designed to provide that evidence.
The primary endpoint was first occurrence of MACE: cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. After a median follow-up of 39.8 months, MACE occurred in 6.5% of the semaglutide arm versus 8.0% of placebo (hazard ratio 0.80, 95% CI 0.72–0.90; P<0.001).
WHY THIS MATTERS BEYOND DIABETES
Prior landmark GLP-1 cardiovascular trials — LEADER (liraglutide), SUSTAIN-6, and PIONEER 6 — all enrolled diabetic patients. SELECT was the first to prove cardiovascular benefit in a non-diabetic obese population. This is a category shift: it reframes GLP-1 agonists not just as metabolic agents but as primary cardiovascular risk-reduction therapy — conceptually similar to how statins are used regardless of whether a patient has elevated cholesterol symptoms.
Critically, the cardiovascular benefit in SELECT appeared to begin accumulating before significant weight loss occurred. This early divergence of the MACE curves suggests mechanisms beyond weight reduction — potentially direct anti-inflammatory effects, improved endothelial function, or direct cardiac effects of GLP-1 receptor activation. The mechanistic question remains active research.
FDA LABEL UPDATE AND ACCESS IMPLICATIONS
Based on SELECT data, the FDA updated the prescribing information for semaglutide 2.4mg (Wegovy) in 2024 to include a cardiovascular risk reduction indication — making it one of the few non-statin, non-blood pressure agents with an approved cardiovascular indication. This expanded the insurance coverage population: patients who qualified for Wegovy on cardiovascular risk grounds but not purely on BMI thresholds gained a new reimbursement pathway.
Semaglutide is a synthetic analogue of the human GLP-1 hormone — a 30-amino acid peptide naturally released from the intestinal L-cell. The SELECT findings have revived interest in cardiovascular peptide biology broadly, including potential complementary effects from GIP-receptor agonism in tirzepatide, whose own cardiovascular trial (SURPASS-CVOT) has since published.
Sources & References
